ATE373672T1 - Synthese von methoxynukleoside und enzymatische nukleisäure moleküle - Google Patents

Synthese von methoxynukleoside und enzymatische nukleisäure moleküle

Info

Publication number
ATE373672T1
ATE373672T1 AT01103093T AT01103093T ATE373672T1 AT E373672 T1 ATE373672 T1 AT E373672T1 AT 01103093 T AT01103093 T AT 01103093T AT 01103093 T AT01103093 T AT 01103093T AT E373672 T1 ATE373672 T1 AT E373672T1
Authority
AT
Austria
Prior art keywords
nucleic acid
synthesis
acid molecules
enzymatic nucleic
methoxynucleosides
Prior art date
Application number
AT01103093T
Other languages
English (en)
Inventor
Francine Wincott
Leonid Beigelmann
Jasenka Matulic-Adamic
Nassim Usman
Peter Haeberli
Alexander Karpeisky
David Sweedler
Thale Jarvis
Anthony Direnzo
Original Assignee
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/585,682 external-priority patent/US5728818A/en
Priority claimed from US08/632,882 external-priority patent/US5998203A/en
Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc
Application granted granted Critical
Publication of ATE373672T1 publication Critical patent/ATE373672T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01103093T 1996-01-16 1996-12-23 Synthese von methoxynukleoside und enzymatische nukleisäure moleküle ATE373672T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/585,682 US5728818A (en) 1996-01-16 1996-01-16 Chemical linkage of ribozyme protions
US60042996A 1996-02-13 1996-02-13
US08/632,882 US5998203A (en) 1996-04-16 1996-04-16 Enzymatic nucleic acids containing 5'-and/or 3'-cap structures

Publications (1)

Publication Number Publication Date
ATE373672T1 true ATE373672T1 (de) 2007-10-15

Family

ID=27416459

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01103093T ATE373672T1 (de) 1996-01-16 1996-12-23 Synthese von methoxynukleoside und enzymatische nukleisäure moleküle

Country Status (6)

Country Link
EP (2) EP1108724B1 (de)
AT (1) ATE373672T1 (de)
AU (1) AU1430097A (de)
CA (1) CA2253382A1 (de)
DE (1) DE69637256T2 (de)
WO (1) WO1997026270A2 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6656731B1 (en) 1997-09-22 2003-12-02 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid catalysts with endonuclease activity
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6482932B1 (en) * 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
WO1999054459A2 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
JP2002512794A (ja) * 1998-04-29 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み
EP1098969A2 (de) * 1998-07-20 2001-05-16 Ribozyme Pharmaceuticals, Inc. Verwendung von nukleinsäure moleküle als antivirale mitteln
US6130324A (en) * 1998-08-11 2000-10-10 University Of Utah Research Foundation Amphipathic oligonucleotides and polynucleotides having potent antiviral activity
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
JP2004512810A (ja) * 1999-08-31 2004-04-30 サーナ・セラピューティクス・インコーポレイテッド 核酸に基づく遺伝子発現の調節剤
US6831171B2 (en) 2000-02-08 2004-12-14 Yale University Nucleic acid catalysts with endonuclease activity
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2005041859A2 (en) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery.
WO2001062911A2 (en) * 2000-02-24 2001-08-30 Ribozyme Pharmaceuticals, Inc. Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
AU2001283222A1 (en) * 2000-08-09 2002-02-18 Ribozyme Pharmaceuticals, Incorporated Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
AU2001286959B2 (en) 2000-09-01 2007-09-06 Ribozyme Pharmaceuticals, Incorporated Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1572067A4 (de) 2001-05-18 2009-05-13 Sirna Therapeutics Inc Konjugate und zusammensetzungen für die zelluläre freisetzung
AU2002315393A1 (en) 2001-06-21 2003-01-08 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
DE60216798T2 (de) * 2001-10-29 2007-10-18 Mcgill University, Montreal Azyklische linker enthaltende oligonukleotide und deren verwendungen
US7071311B2 (en) 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
EP2322657B1 (de) 2005-06-28 2014-11-05 Medtronic, Inc. Verfahren und Nukleotid-Sequenzen, die die Expression mutiertes Huntigtin-Genes in bevorzugter Weise unterdrücken.
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
WO2007027775A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
CA2647728C (en) 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
EP2061901A2 (de) 2006-10-31 2009-05-27 Noxxon Pharma AG Verfahren zum nachweis eines einzel- oder doppelsträngigen nukleinsäuremoleküls
US20100093836A1 (en) 2007-01-29 2010-04-15 Isis Pharmaceuticals, Inc Compounds and methods for modulating protein expression
WO2009045469A2 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
LT2494993T (lt) 2007-05-04 2018-12-27 Marina Biotech, Inc. Aminorūgščių lipidai ir jų panaudojimas
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
WO2009123764A2 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
JP2011521649A (ja) 2008-05-30 2011-07-28 イェール ユニバーシティー 遺伝子発現を改変するための標的化オリゴヌクレオチド組成物
EP2633864A1 (de) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
EP2349210B1 (de) 2008-10-16 2015-03-18 Marina Biotech, Inc. Verfahren und zusammensetzungen zur liposomalen und effizienten zuführung von gene-silencing-therapeutika
WO2010048585A2 (en) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
US20100215660A1 (en) 2009-02-23 2010-08-26 Sarwar Hashmi Kruppel-like factors and fat regulation
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
CN115227709A (zh) 2009-06-17 2022-10-25 冷泉港实验室 用于在对象中调节smn2剪接的组合物和方法
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
JP5685267B2 (ja) * 2009-12-09 2015-03-18 日東電工株式会社 Ｈｓｐ４７発現の調節
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
JP2013529181A (ja) 2010-03-25 2013-07-18 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 神経障害を治療するための組成物および方法
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
EP2380595A1 (de) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Zusammensetzungen und Verfahren zur selektiven Abgabe von Oligonukleotidmolekülen an spezifische Neuronentypen
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139710A1 (en) 2010-04-26 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds with conformationally restricted monomers and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
SG11201401314PA (en) 2011-09-07 2014-09-26 Marina Biotech Inc Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
WO2013090457A2 (en) 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2797948B1 (de) 2011-12-27 2019-02-20 The J. David Gladstone Institutes Zusammensetzungen zur verwendung in der regulierung des glukosemetabolismus
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (de) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmazeutische kombinationen mit einem thionucleotidanalog
KR101520383B1 (ko) 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
ES2967530T3 (es) 2012-10-26 2024-04-30 Palomo Ltd Composiciones y métodos para el tratamiento de la enfermedad de Parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas
EP2911697A1 (de) 2012-10-26 2015-09-02 Nlife Therapeutics S.L. Zusammensetzungen und verfahren zur selektiven abgabe von oligonukleotidmolekülen an zelltypen
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
EP4059521A1 (de) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur diagnose und behandlung von tumoren
WO2015074010A2 (en) 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
DE102015009929A1 (de) 2015-07-28 2017-02-02 Erdmann Technologies Gmbh Katalytische Oligonukleotide mit Cap-Strukturen
WO2017023861A1 (en) 2015-08-03 2017-02-09 The Regents Of The University Of California Compositions and methods for modulating abhd2 activity
EP3147364A1 (de) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antivirale wirkstoffe mit einem oligonukleotid-lipid-konjugat-bildenden g-quadruplex
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
CA3007152A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
SG10202008046UA (en) 2015-12-23 2020-09-29 Univ Queensland Technology Nucleic acid oligomers and uses therefor
US10858656B2 (en) 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
WO2017173325A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Phosphatidylinositol-3-kinase nucleic acids and uses thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US20170283476A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Myc nucleic acids and uses thereof
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
CA3059882A1 (en) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3461487A1 (de) 2017-09-29 2019-04-03 Nlife Therapeutics S.L. Zusammensetzungen und verfahren zur abgabe von mrna an leberzellen
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CA3137715A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
KR20230107296A (ko) 2020-11-09 2023-07-14 1이 테라퓨틱스 엘티디. 촉매 서열에 기반한 박테리아 감염을 치료 또는 예방하는 방법
WO2022130388A2 (en) 2020-12-18 2022-06-23 Yeda Research And Development Co. Ltd. Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same
IL304068A (en) 2020-12-28 2023-08-01 1E Therapeutics Ltd DNA enzymes against p21 messenger RNA
AU2021411103B2 (en) 2020-12-28 2025-04-24 1E Therapeutics, Ltd. P21 mrna target areas for silencing
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
CN115851855A (zh) 2022-08-24 2023-03-28 凯莱英医药集团（天津）股份有限公司 酶催化合成嘌呤核苷的方法及组合物
EP4735602A2 (de) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung eines auf prkag2 abzielenden antikörper-oligonukleotid-konjugat-abstrahs
CN121793987A (zh) 2023-06-30 2026-04-03 艾维迪提生物科学公司 使用pln靶向性抗体-寡核苷酸缀合物的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0717994A (ja) * 1993-06-30 1995-01-20 Tokyo Yatsuka Univ デオキシリボヌクレオシド誘導体の合成法
CA2192950A1 (en) * 1994-06-22 1995-12-28 Danny P.C. Mcgee Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement

Also Published As

Publication number Publication date
EP0886641A2 (de) 1998-12-30
AU1430097A (en) 1997-08-11
EP1108724A2 (de) 2001-06-20
WO1997026270A3 (en) 1997-11-20
EP1108724B1 (de) 2007-09-19
DE69637256T2 (de) 2008-06-19
EP1108724A3 (de) 2003-01-08
CA2253382A1 (en) 1997-07-24
DE69637256D1 (de) 2007-10-31
WO1997026270A2 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
BR9510003A (pt) Moléculas de dna enzimático
PT920498E (pt) Adn regulador transcricional de ef-1x de hamster
BR9710993A (pt) Derivados anticonvulsivos úteis no tratamento de esclerose lateral amiotrófica (als)
BR9709115A (pt) Moduladores de regeneração de tecido
ATE323180T1 (de) Katalytische nukleinsäure und deren medizinische verwendung
ATE443136T1 (de) Methode für dna synthese
PL328239A1 (en) Methods of and compositions for analysing nucleic acid molecules using techniques of separation according to molecule size
DK0960192T3 (da) Syntetiske polynukleotider
ATE211174T1 (de) Thymidin-kinase-mutanten
EP0645622A3 (de) DNA-Basen-Analysegerät.
DE69507618D1 (de) Fester träger-reagenzien zur synthese von 3'-stickstoffhaltigen polynukleotiden
MX9806041A (es) Proteina purificada sr-p70.
IL138216A0 (en) Novel fdrg protein and nucleic acid molecules and uses therefor
ES2187939T3 (es) Moleculas aisladas de acido nucleico codificantes de miembros de la familia ssx y utilizaciones de las mismas.
DK0647654T3 (da) Anomere fluor-ribosylaminer
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
DE69834813D1 (de) Parvovirus-Vektoren und deren Verwendung
EP0996742A4 (de) Verfahren zur spaltung von dna mittels nukleotid-integrasen
DE69701318D1 (de) Verfahren zur Synthese von Wasserstoffperoxid
DE69814097D1 (de) Universale Polymere Träger zur Synthese von Oligonukleotiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties